MONDAY, JUNE 1, 2026|No. 1131
Market · China · Hypertension

China Hypertension Management Market Reaches 20 Billion Yuan Amid Rising Patient Numbers

China's hypertension management market has grown to approximately 20 billion yuan, driven by an increasing patient base of 272 million as of 2025.

A chart showing the rising number of hypertension patients in China from 2019 to 2025. · Photo by Christian Lue on Unsplash
1 sources
Pipeline ingest
3 reads
Positive / Neutral / Negative
1 countries
Related coverage

2026 China Chronic Disease Management Industry Sub-segment Hypertension Management Market Status Analysis: High Demand Operation, Diversified Supply Coexisting [Picture]

Major listed companies in the industry: Ping An Good Doctor (01833.HK); Alibaba Health (00241.HK); Meinian Onehealth (002044), etc.

Core data of this article: Number of discharged hypertension patients; market size of hypertension management, etc.

Hypertension Disease Demand Analysis

In recent years, with the acceleration of hypertension education and the improvement of medication levels in China, the management awareness of hypertension among most elderly people has improved, objectively driving the steady growth of China's hypertension treatment market. However, the trend of younger hypertension patients continues to significantly increase the prevalence of hypertension in China. From 2019 to 2025, the number of hypertension patients in China increased from 242 million to 272 million, with aging and lifestyle changes steadily raising the prevalence rate.

Chart 1: Number of hypertension patients in China (unit: 10,000 people, %)

In recent years, scholars have continuously shown that hypertension has serious harmful effects:

Chart 2: Research and harmfulness of hypertension in China

Market Size of Hypertension Management

Based on the proportion of discharged hypertension patients in overall diseases and combined with the national medical and health expenditure, the market size of China's hypertension disease management market is approximately 20 billion yuan.

Chart 3: Market size of hypertension management in China (unit: 100 million yuan)

Companies Involved in Hypertension Management

China's hypertension management market presents a diversified competitive landscape where traditional pharmaceutical companies, professional health service institutions, and digital technology newcomers coexist. Pharmaceutical companies leverage core drug varieties to build a moat in the out-of-hospital market and accelerate digital transformation. Traditional hardware giants such as Omron deepen community health services. Emerging technology companies represented by Jiuan Medical (002432.SZ) and Lingxi Biotechnology enter the continuous monitoring and prevention end through the "smart hardware + AI platform + cloud service" model. Meanwhile, the embedding of medical insurance payment scenarios (such as Yiwei Technology's medical insurance face-scanning for file creation) is reshaping service accessibility.

Chart 4: Introduction of companies participating in hypertension management market

Hypertension Chronic Disease Management Models

Common hypertension chronic disease management models include hospital-community integrated management model, internet-based remote management model, and family doctor contract service management model.

Chart 5: Hypertension chronic disease management models

For more research and analysis on this industry, see the forward-looking industry research institute's "China Chronic Disease Management Industry Market Prospects and Investment Strategic Planning Analysis Report." In addition, the forward-looking industry research institute also provides industrial big data, industrial research reports, industrial planning, park planning, industrial investment promotion, industrial atlas, smart investment promotion systems, industry status certification, IPO consulting/募投 feasibility research, IPO working paper consulting, and other solutions. When citing the content of this article in any public disclosure information such as prospectuses and company annual reports, authorization from the forward-looking industry research institute must be obtained.

PAN's pipeline reviewed approximately 1 open sources for this article. No human editor reviewed this article before publication.

Related Reads

Show on timeline →